Objectives: Peptides derived from the C-terminal heptad repeat (CHR) of HIV-1 gp41 are potent fusion inhibitors. We have recently demonstrated that the unique M-T hook structure preceding the pocket-binding motif of CHR peptide-based inhibitors can greatly improve their antiviral activity. In this study, we applied the M-T hook structure to optimize sifuvirtide (SFT), a potent CHR-derived inhibitor currently under Phase III clinical trials in China.
Introduction
More than 60 million people have been infected by HIV-1 and 25 million people have died of AIDS-related diseases (www.unaids. org). Six classes of HIV-1 inhibitors in clinics are directed against four specific steps of the viral life cycle, including cell entry, reverse transcription, integration and virion maturation. 1, 2 Different from other classes of anti-HIV drugs that act after infection occurs, HIV-1 entry inhibitors intercept the virus before it invades the target cells. 3, 4 Currently, there are two HIV-1 entry inhibitors for clinical use: maraviroc (UK-427857), approved in 2007, binds to the cell coreceptor CCR5 thus blocking the binding of virus; 5, 6 and enfuvirtide (T20), a 36 amino acid peptide derived from the C-terminal heptad repeat (CHR) region of HIV-1 transmembrane protein gp41 (Figure 1 ), binds to the N-terminal heptad repeat (NHR) region of gp41 thus preventing the formation of viral fusion core, the gp41 six helix bundle (6-HB). 7 -9 Approved in April 2003, enfuvirtide is the first and only fusion inhibitor used in combination therapy of HIV-1 infection. However, enfuvirtide requires high dosages and drug resistance is easily acquired, 10 -13 calling for a next generation of HIV-1 fusion inhibitors.
A series of novel HIV-1 fusion inhibitors have been created by using the CHR-derived peptide C34 as a template. 14 -16 The rationale is based on the following: (i) the protease-resistant C34 was used to determine the first gp41 structure (6-HB), thus representing a core sequence of the CHR; 17, 18 (ii) C34 contains the NHR pocket-binding motif at its extreme N-terminus, thus stabilizing the interaction of inhibitor with the target site; 17, 19, 20 and (iii) C34 has higher potency than enfuvirtide to inhibit both wild-type and enfuvirtide-resistant HIV-1 isolates. 13, 16, 21 Based on the threedimensional structure of gp41, sifuvirtide (SFT) was designed by introducing multiple salt bridges into C34 and further incorporating a serine residue into its N-terminus. 22 Compared with its parental peptide, sifuvirtide exhibited significantly improved antiviral activity and pharmaceutical profiles. 22 Our crystallographic studies have provided the structural basis for sifuvirtide, confirming the original design strategy of the peptide and revealing the key motifs responsible for its stability and antiviral activity. 23 Indeed, several novel interhelix salt bridges and hydrogen bonds improve the binding affinity of sifuvirtide for the target NHR region and the extra serine residue stabilizes the N-terminal portion of the peptide. 23 Sifuvirtide has already been advanced into clinical Phase III trials in China. However, it was also found that sifuvirtide had a relatively low genetic barrier to induction of drug resistance. 24 In in vitro selection, a panel of sifuvirtide-resistant HIV-1 variants could be easily obtained. 24 Similar to enfuvirtide, the responsible mutations of sifuvirtide resistance were largely mapped to the inhibitor binding sites in the NHR, which overlapped with enfuvirtide-resistant mutations either singly or in combination, such as I37T, V38A, N43K and I37T/ N43K (according to HIV-1 HXB2 gp41 numbering throughout). 10 -12 Therefore, new strategies or concepts are eagerly wanted to develop HIV-1 fusion inhibitors that not only inhibit the existing resistant HIV-1 variants but also possess high genetic barriers to induction of drug resistance.
We previously identified that the CHR-derived peptide CP32 (i.e. CP621-652) had a much higher binding affinity than C34 for the NHR target. 25 Following that we designed CP32M, which exhibited a significantly improved anti-HIV activity especially against enfuvirtide-resistant viruses. 26 Recently, we determined the crystal structure of CP32 and identified that the residues Met115 and Thr116 preceding the pocket-binding domain (PBD) of the peptide forms a hook-like structure, named the M-T hook. 27 We also demonstrated that addition of the M-T hook structure to the N-termini of C34 or the short peptide SC22EK could greatly increase the binding affinity and antiviral activity of the inhibitors, 28, 29 addressing the importance of the M-T hook as a vital strategy to design or optimize HIV-1 fusion inhibitors. In this study, we engineered sifuvirtide by adding the M-T hook to improve its pharmaceutical profiles. The high-resolution crystal structures confirmed the M-T hook conformation presented at the N-terminus of sifuvirtide. We demonstrated that the M-T hook structure markedly enhanced the binding affinity and anti-HIV activity of sifuvirtide, especially against those sifuvirtide-and enfuvirtide-resistant HIV-1 mutants. Significantly, the resulting peptide (MT-SFT) had an increased genetic barrier compared with sifuvirtide to the development of resistance.
Materials and methods

Peptide synthesis
The CHR-derived peptides enfuvirtide, sifuvirtide, MT-SFT, C34 and MT-C34 and the NHR-derived peptides N41, N36 and N36 mutants (I37T, V38A, Q40H, N43K, I37T/N43K and V38A/N42T) were synthesized by a standard solid-phase Fmoc method as described previously. 28 All peptides were acetylated at the N-terminus and amidated at the C-terminus. They were purified by reversed-phase HPLC and verified for purity .95% and correct amino acid composition by mass spectrometry. The concentrations of the peptides were determined by UV absorbance and a theoretically calculated molar extinction coefficient 1 (280 nm) of 5500 and 1490 M -1 cm
based on the number of tryptophan and tyrosine residues, respectively.
Structure determination of the 6-HB-containing MT-SFT
In order to determine the crystal structure of 6-HBs formed by MT-SFT/N36 and MT-SFT/N41, MT-SFT peptide and its NHR counterparts (N36 or N41), synthetic peptides MT-SFT/N36 or MT-SFT/N41 were mixed at 1 : 1 molar ratio and were dissolved in denaturing buffer containing 100 mM NaH 2 PO 4 , 10 mM Tris HCl pH 8.0 and 8 M urea, respectively. The refolding was carried out by dialysis against refolding buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl at 48C overnight, yielding soluble 6-HBs. The 6-HBs were finally purified by size-exclusion chromatography (Superdex 75 10/300 GL, GE Healthcare). A predominant peak corresponding to the size of the 6-HB was collected and concentrated prior to crystallization trials. The 6-HB composed of MT-SFT/N36 was crystallized by mixing equal volumes (1 mL) of the concentrated sample ( 10 mg/mL) and reservoir solution containing 0.14 M calcium chloride, 0.1 M sodium acetate (pH 4.6) and 18% (v/v) 2-propanol at 228C. The cryocooling was carried out by soaking the crystals for 60 s in reservoir solution containing 15% glycerol followed by flash freezing in liquid nitrogen. The 6-HB composed of MT-SFT/N41 was crystallized by mixing equal volumes (1 mL) of purified sample ( 10 mg/mL) and reservoir solution containing 0.1 M MES buffer pH 6.4, 26% (v/v) PEG 4000 in a hanging drop vapour diffusion system at 228C. The cryocooling was carried out by soaking the crystals for 40 s in reservoir solution containing 15% glycerol followed by flash freezing in liquid nitrogen. Complete datasets for the MT-SFT/N36 and MT-SFT/ N41 complexes were collected at beamline X10SA, Swiss Light Source at Paul Scherrer Institute using X-rays with a wavelength of 1.000 Å . The crystal structure containing MT-SFT/N36 and MT-SFT/N41 was solved by molecular replacement (Phaser for MR, CCP4 package) using the crystal structure of sifuvirtide (PDB ID: 3VIE) as the searching models, which yielded the interpretable electron-density maps. Both structures were refined (PHENIX) to finalize the atomic models with excellent refinement statistics and stereochemical qualities and validated by MolProbity analysis (Table S1 , available as Supplementary data at JAC Online). The MolProbity scores for the crystal structures of the 6-HBs containing MT-SFT/N36 and MT-SFT/ N41 are 1.37 and 1.24, rating 93rd and 96th percentiles among structures of comparable resolution, respectively. The Ramachandran plots of both structures find all residues in the favoured area.
Circular dichroism (CD) spectroscopy
CD spectroscopy was performed according to the protocol described previously. 30 Briefly, a CHR peptide (C34, SFT or MT-SFT) was incubated with an equal molar concentration of NHR peptide N36 or its mutant (I37T, V38A, Q40H, N43K, I37T/N43K and V38A/N42T) at 378C for 30 min. The final concentration of each peptide was 10 mM in PBS buffer (pH 7.2). The CD spectra were acquired on a Jasco spectropolarimeter (model J-815) using a 1 nm bandwidth with a 1 nm step resolution from 195 to 260 nm at room temperature. The spectra were corrected by subtraction of a blank corresponding to the solvent. The data were averaged over three accumulations. The a-helical content was calculated from the CD signal by dividing the mean residue ellipticity [u] at 222 nm by the value expected for 100% helix formation (233 000 degrees.cm 2 .dmol 21 ). The thermal denaturation was performed by monitoring the ellipticity [u] at 222 nm from 20-988C using a temperature controller. The temperature was increased at a rate of 1.28C/min; data were acquired at a 1 nm bandwidth at 222 nm at a frequency of 0.25 Hz. The melting curve was smoothed and the midpoint of the thermal unfolding transition (T m ) values was taken as the maximum of the derivative d[u] 222 /dT. The T m value was detected at a peptide concentration of 10 mM in PBS buffer.
Isothermal titration calorimetry (ITC)
ITC assay was performed using an iTC200 microcalorimeter instrument (MicroCal, USA) as described previously. 28 Briefly, 1 mM N36 dissolved in double-distilled H 2 O (ddH 2 O) was injected into the chamber containing 100 mM sifuvirtide or MT-SFT. The experiments were carried out at 258C. The time between injections was 240 s and the stirring speed was 500 rpm. The heats of dilution were determined in control experiments by injecting N36 into ddH 2 O and subtracted from the heats produced in the corresponding peptide-peptide binding experiments. Data acquisition and analysis were performed using MicroCal Origin software (version 7.0).
Cell-cell fusion assays
293Teffector cells seeded in six-well plates at 4×10 5 cells/well were transfected with the plasmid encoding HIV-1 NL4-3 Env. The day after transfection, the effector cells were incubated with MT-4 cells at a ratio of 1 : 3 in 96-well plates in the presence or absence of tested peptides. After coculturing for an additional 48 h at 378C, the syncytia of each well were counted under a microscope. The percentage inhibition of fusion by the peptides and 50% inhibitory concentration (IC 50 ) values of fusion were calculated using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
HIV-1 single-cycle infection
HIV-1 pseudoviruses were generated as described previously. 31 Briefly, 293T cells were co-transfected with an Env-expressing plasmid and a backbone plasmid pSG3
Denv that encodes Env-defective, luciferase-expressing HIV-1 genome using Lipofectamine 2000 reagent (Invitrogen). Pseudoviruscontaining culture supernatants were harvested 48 h after transfection and filtered using a 0.45 mm pore size. The 50% tissue culture infectious dose (TCID 50 ) of the pseudovirus was determined in TZM-bl cells. The inhibitory activity of sifuvirtide and MT-SFT was determined using TZM-bl cells. Briefly, the peptides were prepared with 10 series dilutions in a 3-fold stepwise manner and mixed with 100 TCID 50 viruses and incubated for 1 h at room temperature. The mixture was added to TZM-bl cells (10 4 /well) and incubated at 378C for 48 h before the luciferase activity was measured as described previously. 31 
Inhibition of HIV-1 NL4-3 infection
The molecular clone of wild-type or drug-resistant HIV-1 NL4-3 was prepared by transfection of pNL4-3 plasmid into 293T cells. The virus stock was harvested 48 h post-transfection and quantified for TCID 50 . Inhibition of infection by sifuvirtide and MT-SFT on HIV-1 NL4-3 was performed as described for pseudovirus. Briefly, 100 TCID 50 viruses were used to infect TZM-bl cells in the presence or absence of serially diluted peptides. Two days post-infection, the cells were harvested and lysed in reporter lysis buffer and the luciferase activity was measured.
Inhibition of 6-HB formation by peptides
A mouse monoclonal antibody specific for the gp41 6-HB (NC-1) was obtained from Dr Shibo Jiang through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health. The inhibitory activity of CHR peptides on the 6-HB formation was measured by a modified ELISA-based method as described previously. 30 Briefly, a 96-well polystyrene plate (Costar, Corning Inc., Corning, NY, USA) was coated with NC-1 (2 mg/mL in 0.1 M Tris, pH 8.8). A tested peptide (sifuvirtide or MT-SFT) at graded concentrations was mixed with C34-biotin (0.1 mM) and incubated with N36 (0.1 mM) at room temperature for 30 min. The mixture was then added to the NC-1-coated plate, followed by incubation at room temperature for 30 min and washing with a washing buffer (PBS containing 0.1% Tween 20) three times. Then, horseradish peroxidase-labelled streptavidin (Invitrogen) and the substrate 3,3,5,5-tetramethylbenzidine (Sigma) were added sequentially. Absorbance at 450 nm was measured using an ELISA reader (Bio-Rad).
Induction of inhibitor-resistant HIV-1 variants
The in vitro selection of peptide inhibitor-resistant HIV-1 variants was performed as described previously. 24 Briefly, MT-4 cells were seeded at 1×10
Results
The structure of the N-terminal M-T hook-capped SFT
To optimize sifuvirtide, we replaced the N-terminal serine of sifuvirtide by residues methionine (M) and threonine (T), resulting in a novel peptide named MT-SFT (Figure 1) . We first performed crystallographic studies to determine whether the incorporated residues adopt the M-T hook structure. As shown in Figure 2 (a), MT-SFT formed a typical 6-HB structure with N36 as anticipated. The central N36 trimeric coiled coil is fully wrapped by three MT-SFT peptides in an antiparallel orientation. MT-SFT/N41 also formed a 6-HB structure, regardless that the counterpart of a C-terminal portion of MT-SFT is unavailable on the N41 trimer (Figure 3a) . When performing the molecular replacement using the crystal structure of sifuvirtide (without the M-T hook) as the searching model, the resulting electron-density map showed strong Fo-Fc positive peaks at the N-terminus of sifuvirtide. The positive densities map clearly indicated the shape for a typical M-T hook structure. After manual model building and refinements, we confirmed that the N-terminal residues Met115 and Thr116 adopt the M-T hook structure in both complexes ( Figure 2a and b and Figure 3a and b). Briefly, the threonine terminates the a-helical conformation of MT-SFT by rotating its dihedral angle c nearly 1808. Consequently, the N-termini of MT-SFT are directed away from the central coiledcoil trimer. The conformation of the threonine is stabilized by an important hydrogen bond between its side-chain hydroxyl group and the backbone NH group of the downstream residues at i+ 3 position (Thr116-Thr119 in MT-SFT/N36, distance: 2.27 Å , angle: 165.38; Thr116 -Thr119 in MT-SFT/N41, distance: 2.76 Å , angle: 165.18). As the result of the unusual conformation of Thr116, the upstream methionine is then positioned on top of the left side of the hydrophobic pocket on the NHR coiled-coil trimer, so that its hydrophobic side chain can accommodate the hydrophobic groove between the NHR and CHR helices, stabilizing the hydrophobic pocket on the NHR trimer. The N-terminal portions of NHR-bound MT-SFT could be perfectly superimposed on that of CP32, MT-C34 and MT-SC22EK, which contain the M-T hook structure.
The M-T hook greatly enhances the binding of sifuvirtide
Compared with the template peptide C34, the binding affinity of sifuvirtide for the NHR target was markedly enhanced. Thus, it was intriguing to know whether the M-T hook structure can further enhance the binding of sifuvirtide. To this end, we applied CD spectroscopy and ITC experiments. First, the a-helicity and thermostability of the 6-HB core formed by MT-SFT and the NHR-derived peptide N36 were measured by CD spectroscopy in comparison with sifuvirtide and C34-based 6-HBs. The peptide pairs (MT-SFT/N36, sifuvirtide/N36 and C34/N36) were mixed at equal molar concentrations and incubated at 378C for 30 min. As shown in Figure 4(a) , the CD spectra of all three peptide pairs displayed typical double minima at 208 and 222 nm, which indicated the formation of the secondary a-helical structures. The thermostability of each 6-HB, defined as the T m value, was measured ( Figure 4b) . Consistently, sifuvirtide-based 6-HB had a significantly increased T m value (72.28C) as compared with C34-based 6-HB (65.38C). Strikingly, the T m value of MT-SFT-based 6-HB was further increased up to 81.38C. These results indicated that substitution of the N-terminal residue serine by two M-T hook residues can markedly increase the thermostability of the 6-HB conformation. We then used the ITC technology to determine the thermodynamic profiles of the molecular interaction between the inhibitors and N36. The heat released or absorbed during the interaction allowed an accurate determination of the binding constant (K), reaction stoichiometry (N), enthalpy (DH) and entropy (DS). As shown in Figure 5 , the formation of 6-HBs by sifuvirtide and N36 (Figure 5a ) or MT-SFTand N36 (Figure 5b ) is a typical enthalpy-driven reaction in which a large amount of heat is released. Compared with sifuvirtide, the K value of MT-SFT increased 16.2-fold (from 6.8×10 5 to 1.1×10 7 M 21 ), suggesting a largely increased binding affinity. Therefore, the M-T hook structure critically determines the interaction of the inhibitors with the NHR target.
The M-T hook greatly improves the antiviral activity of sifuvirtide
Based on our biophysical data, we were interested to compare the anti-HIV activity of sifuvirtide and MT-SFT. In the HIV-1 NL4-3 Env-mediated cell -cell fusion assay (Figure 6a The M-T hook increases the potency of sifuvirtide pseudovirus with IC 50 values of 3.2 and 0.9 nM, respectively, indicating a 3.6-fold increase. For the wild-type HIV-1 NL4-3 infection (Figure 6c ), sifuvirtide had an IC 50 of 2.0 nM, whereas MT-SFT had an IC 50 of 0.6 nM, indicating a 3.3-fold increase. These results demonstrated that the M-T hook residues can enhance the anti-HIV activity of sifuvirtide .3-fold. We also showed that MT-SFT possessed potent inhibitory activity against a panel of primary HIV-1 isolates (Table S2 , available as Supplementary data at JAC Online). To further understand the mechanism, we compared the inhibitory activity of sifuvirtide and MT-SFT on the formation of the 6-HB structure. As shown in Figure 6 (d), sifuvirtide blocked 6-HB formation with an IC 50 of 0.9 mM, whereas MT-SFT had an IC 50 value at 0.1 mM. Therefore, we concluded that the M-T hook could confer the inhibitors with high-affinity binding capacity to compete off the viral CHR, and thereby improving the anti-HIV activity.
MT-SFT is a potent inhibitor of drug-resistant HIV-1 variants
We previously found that the M-T hook structure-modified peptides could inhibit drug-resistant HIV-1 variants more efficiently.
28,29
Here, we utilized three panels of HIV-1 mutants to compare sifuvirtide and MT-SFT (Table 1 
High-affinity binding of MT-SFT to the NHR mutants
To gain insights into the mechanism of the M-T hook-modified inhibitors possessing higher potency against drug-resistant HIV-1 variants, we compared the binding affinity of sifuvirtide and MT-SFT for the NHR mutants. A panel of N36-based peptides carrying single (I37T, V38A, Q40H and N43K) or double (I37T/N43K and V38A/N42T) NHR mutations were synthesized and applied in the CD analysis. As shown in Figure 7 , the NHR mutations could result in a sharp decrease in the thermostability of sifuvirtide-based 6-HBs, such as I37T mutant (T m ¼ 57.28C) and Q40H (T m ¼ 61.28C); however, the T m values of MT-SFT-based 6-HBs could be significantly recovered, reaching a degree comparable (I37T, V38A, V38A/N42T) to or greater (Q40H, N43K, I37T/ N43K) than that of SFT/N36-based bundle (72.28C). Therefore, we speculate that the M-T hook structure can compensate the loss of binding affinity in the NHR mutants, thus preserving high activity against sifuvirtide-and enfuvirtide-resistant HIV-1 variants.
The M-T hook significantly increases the genetic barrier to drug resistance
We asked whether the M-T hook structure can confer the inhibitors with a high genetic barrier to developing drug resistance. To address this, we performed a series of passaging experiments to generate virus that was resistant to sifuvirtide or MT-SFT. As shown in Figure 8 (a), sifuvirtide-resistant virus was obtained after 38 generations of passaging, at which time the concentration of sifuvirtide reached up to 9600 nM; in sharp contrast, the virus did not acquire obvious resistance to MT-SFT at the same timepoint. We continued an additional 12 passages to select the virus resistant to MT-SFT, leading to a drug concentration of 800 nM. Further, we validated this finding by comparing the peptide pair C34 and MT-C34 in parallel to induce the resistance. Consistently, the virus culture could be reasonably recovered after 38 passages, wherein the concentration of C34 was escalated up to 3200 nM (Figure 8b ). Consistently MT-C34 only approached 160 nM due to the difficulty of passaging virus. Therefore, we could conclude that the modified peptide inhibitors possessed an increased genetic barrier to the development of resistance.
Discussion
By solving the crystal structure of the peptide CP32-based 6-HB, we surprisingly identified that the hook-like structure attaches to one side of the NHR pocket tightly, thus stabilizing the NHR-CHR interaction. 27 Using peptides C34 and SC22EK as models, we have demonstrated that the M-T hook conformation could be well preserved at the extreme N-termini of peptides and efficiently strengthened the affinity of NHR -CHR interactions. 28, 29 In this study, we incorporated the conserved hook residues in the N-terminus of sifuvirtide and verified again a highly stable M-T hook structure by crystallographic study. MT-SFT was cocrystallized with two different NHR targets, N36 and N41. The N36 trimer can accommodate the entire MT-SFT, whereas the N41 trimer only accommodates the N-terminal part of the inhibitor and leaves 30% of C-terminal a-helices of MT-SFT overhanging (Figure 3 ). However, this did not seem to confound the binding of MT-SFT to The M-T hook increases the potency of sifuvirtide 2765 JAC NHR targets, because both MT-SFT/N36 and MT-SFT/N41 pairs formed stable 6-HB and yielded crystals that were diffracted to high resolution. These data suggest that the crucial region on the NHR is targeted by the N-terminal residues of MT-SFT, in which the M-T hook and PBD play the critical roles. In addition, our findings also suggest a strategy of further optimizing MT-SFT by shortening the peptide from its C-terminus. Although sifuvirtide has already been engineered for high binding, our biophysical data (CD and ITC) indicated that addition of the M-T hook can further fortify the inhibitor binding (Figures 4 and 5 ). Taken together, we believe that the M-T hook presents a general structural feature when placed at the N-terminus of the PBD of the CHR peptides. It is conceivable that the M-T hook may integrate the PBD, thus synergistically enhancing the interactions of CHR-derived inhibitors with the target NHR sequences.
As the first and only clinically approved HIV-1 fusion inhibitor, enfuvirtide has several prominent disadvantages limiting its wide application. 15, 32 First, the antiviral activity of enfuvirtide is generally lower than that of other CHR-derived peptides. Second, it has a short half-life in vivo, thus requiring a dosage of 90 mg twice daily. Third, it has a relatively low genetic barrier to induction of drug resistance. The emergence and spread of enfuvirtideresistant HIV-1 variants resulted in an increased number of patients failing to respond to enfuvirtide treatment. The resistance phenotype is associated mostly with substitutions in amino acids 36 -45 of the NHR, with three contiguous residues (Gly36-Ile27-Val38) being a hotspot. 10 -12,33,34 To overcome the problem of drug resistance, a number of strategies have been pursued to develop novel peptide inhibitors with significantly improved anti-HIV activity and pharmaceutical profiles. 13 -16,21,32 After enfuvirtide, T-1249 was designed as a second-generation fusion inhibitor by adding the PBD at its N-terminus, 35 but its clinical development was discontinued due to formulation difficulties. 36 -38 Based on the C34 sequence, more potent peptides were designed by introducing salt bridges that stabilize the helical conformation of the inhibitors, such as sifuvirtide, 22 SC34EK 39 and T2635. 40 Although these new-generation inhibitors were effective against diverse enfuvirtide-resistant HIV-1 strains, they also induced drug-resistant variants. 24, 41, 42 Previously, the in vitro selection of sifuvirtide-resistant HIV-1 variants identified that most of the substitutions were confined to enfuvirtideresistant positions in the NHR of gp41, including amino acids Ile37, Val38, Gln41 and Asn43 either singly or in combination, and the mutant viruses showed variable degrees of crossresistance to enfuvirtide. 24 Our previous studies demonstrated that the M-T hook-capped peptides, such as MT-C34 and MT-SC22EK, had improved activity against T20-and/or sifuvirtide-resistant HIV-1 variants. 28, 29 Here, our data show that MT-SFT has significantly improved potency compared with sifuvirtide to block 6-HB formation and inhibit HIV-1 Env-mediated cell fusion, viral entry and infection, but more impressively MT-SFT maintained high potency against a large group of enfuvirtide-and sifuvirtide-resistant viruses, including drug-induced and naturally occurring HIV-1 mutants (Table 1) . Consistently, our CD data revealed that MT-SFT interacted with the corresponding NHR mutants with significantly higher stability as compared with sifuvirtide ( Figure 7) . Nonetheless, the most significant point of this study should be that the M-T hook-modified peptides (MT-SFT and MT-C34) had a considerably higher genetic barrier to developing drug resistance. During in vitro selection, the escalating concentrations of the peptides sifuvirtide and C34 were able to easily select resistant viruses, in agreement with previous studies. 24, 43 In a sharp contrast, the addition of the M-T hook residues (MT-SFT and MT-C34) markedly changed the resistance profiles ( Figure 8 ). We have also found that the M-T hook-modified short-peptide inhibitor MT-SC22EK behaved with a similar phenotype (H. Chong, Z. Qiu, J. Sun, Y. Qiao and Y. He, unpublished data). Taken together, we consider that the M-T hook structure can endow the peptide fusion inhibitors with a high genetic barrier to developing resistant HIV-1 variants, which provides an important feature for drug development. Recently, Eggink et al. 44 described four mechanisms of drug resistance, including reduced contact, steric obstruction, electrostatic repulsion and electrostatic attraction. Our studies on the sifuvirtide resistance profile could deduce several additional mechanisms, such as hydrogen bond disruption and hydrophobic contact disruption. 23, 24 It is highly interesting to know how the M-T hook structure changes the Chong et al.
resistance profiles of sifuvirtide and C34. From our structural studies, we could see that M-T hook binds the NHR target in a rather unique way compared with any other region of the peptide. Instead of binding to the groove between two adjacent NHR helices, the M-T hook binds to the side of the hydrophobic pocket as well as the residues on its own PBD region. Therefore, it seems that the M-T hook serves to strengthen the PBD -pocket interaction rather than target novel sites on the NHR trimer. It is well characterized that residues involving PBD -pocket interaction are the most conserved residues during HIV-1 evolution; the mutation of these residues is often lethal to the virus. Thus, the balance between virus survival and drug resistance becomes hard to maintain and the genetic barrier to drug resistance against the M-T hook increases. Although MT-SFT and MT-C34 are currently The M-T hook increases the potency of sifuvirtide 2767 JAC undergoing a delayed selection procedure, they may be gradually escalated to higher concentrations thus resulting in the high-level resistant HIV-1 mutants. We expect to explore the mechanism of HIV-1 resistance to the M-T hook-based peptides by multiple approaches, which would be helpful for understanding the mechanisms of HIV-1 fusion and for designing novel fusion inhibitors.
In conclusion, the significance of our studies includes three aspects. First, we have verified that the M-T hook structure is a general feature of CHR-derived inhibitors. Second, the M-T hook structure plays a vital role for designing fusion inhibitors against enfuvirtide-and sifuvirtide-resistant HIV-1 mutants. Third, the M-T hook-based HIV-1 fusion inhibitors have a high genetic barrier to developing drug resistance.
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